Abstract: To perform a query, a set of nodes for an origin is loaded, it is determined if a node is a destination for each node of the set of nodes, and a path is recorded in response to the node being the destination. A hypothetical path is generated in response to the node not being the destination, it is determined if the hypothetical path exceeds a stopping rule, and the hypothetical path is recorded in response to the hypothetical path not exceeding the stopping rule.

Abstract: To determine if an intermediate stop in a multistop travel itinerary is a layover or an intermediate destination, a passenger utility value is calculated for the intermediate stop and the passenger utility value for the intermediate stop is compared to a passenger utility for a layover. The intermediate stop is determined to be a layover in response to the passenger utility value for the intermediate stop being greater than or equal to the passenger utility for a layover and the intermediate stop is determined to be an intermediate destination in response to the passenger utility value for the intermediate stop being less than the passenger utility for a layover.

Abstract: To determine if an intermediate stop in a multistop travel itinerary is a layover or an intermediate destination, a passenger utility value is calculated for the intermediate stop and the passenger utility value for the intermediate stop is compared to a passenger utility for a layover. The intermediate stop is determined to be a layover in response to the passenger utility value for the intermediate stop being greater than or equal to the passenger utility for a layover and the intermediate stop is determined to be an intermediate destination in response to the passenger utility value for the intermediate stop being less than the passenger utility for a layover.

Abstract: Devices for redesigning a travel network having a plurality of origin-destination pairs are described. In particular, a surplus determining device is configured to determine the consumer surplus generated by an additional path added to a first origin-destination pair within the travel network using observable utility components of a consumer utility model.

Abstract: Devices for redesigning a travel network having a plurality of origin-destination pairs are described. In particular, a surplus determining device is configured to determine the consumer surplus generated by an additional path added to a first origin-destination pair within the travel network using observable utility components of a consumer utility model.

Abstract: Techniques for determining constrained market allocation for a travel network having a plurality of origin-destination market pairs include using a first device that computes constrained market allocation based on the capacity of at least a first leg of the travel network and the passenger utility of at least one path that includes the first leg.

Abstract: This invention relates to the compounds of 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)methyloxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxyphenylsilyl)methyloxy]phenol, polymorphs thereof and their pharmaceutically acceptable salts, useful as antiatherosclerotic agents.

Abstract: The present invention provides compounds of the formula ##STR1## wherein R is hydrogen or --C(O)--(CH.sub.2).sub.m --Q wherein Q is hydrogen or --COOH and m is an integer 1, 2, 3 or 4;R.sub.1, R.sub.5 and R.sub.6 are independently a C.sub.1 -C.sub.6 alkyl group;R.sub.2, R.sub.3 and R.sub.4 are independently hydrogen or a C.sub.1 -C.sub.6 alkyl group;Z is thio, oxy or a methylene group;A is a C.sub.1 -C.sub.4 alkylene group;X is thio or oxy; andG.sub.1 and G.sub.2 are independently hydrogen, C.sub.1 -C.sub.6 alkyl or --C(O)--(CH.sub.2).sub.n --CH.sub.3 and n is an integer 0, 1, 2 or 3;or a pharmaceutically acceptable salt thereof; useful for the treatment of atherosclerosis and chronic inflammatory disorders; for inhibiting cytokine-induced expression of VCAM-1 and/or ICAM-1; for inhibiting the peroxidation of LDL lipid; for lowering plasma cholesterol; and as anti-oxidant chemical additives useful for preventing oxidative deterioration in organic materials.

Abstract: The present invention provides compounds of the formula ##STR1## wherein X is selected from the group consisting of ##STR2## Y is thio, oxy or a methylene group; Z is hydrogen or --C(O)--(CH.sub.2).sub.m --Q wherein Q is hydrogen or --COOH and m is an integer 1, 2, 3 or 4;R.sub.1 is C.sub.1 -C.sub.6 alkyl; andR.sub.2, R.sub.3 and R.sub.4 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl;or a stereoisomer thereof; useful for the treatment of atherosclerosis and chronic inflammatory disorders; for inhibiting cytokine-induced expression of VCAM-1 and/or ICAM-1; for inhibiting the peroxidation of LDL lipid; for lowering plasma cholesterol; and as anti-oxidant chemical additives useful for preventing oxidative deterioration in organic materials.

Abstract: A method of lowering plasma cholesterol level in a patient with hypercholesterolemia, by administration of a compound of formula (1) ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group;Z is a thio, oxy or methylene group;A is a C.sub.1 -C.sub.4 alkylene group; andR.sub.5 is a C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.n --(Ar)wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or napthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro or C.sub.1 -C.sub.6 alkyl.

Abstract: A method of lowering plasma cholesterol level in a patient with hypercholesterolemia, by administration of a compound of formula (1) ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group;Z is a thio, oxy or methylene group;A is a C.sub.1 -C.sub.4 alkylene group; andR.sub.5 is a C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.n --(Ar)wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or napthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro or C.sub.1 -C.sub.6 alkyl.

Abstract: This invention relates to compounds of the formula ##STR1## wherein R.sub.1 and R.sub.6 are each independently C.sub.1 -C.sub.6 alkyl;R.sub.2, R.sub.3 and R.sub.4 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl;R is hydrogen or --C(O)--(CH.sub.2).sub.m --Q wherein Q is hydrogen or --COOH and m is an integer 1, 2, 3 or 4;Z is a thio, oxy or methylene group;A is a C.sub.1 -C.sub.4 alkylene group;R.sub.5 and R.sub.7 are each independently a C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.n --(Ar) wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or naphthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, halogen, trifluoromethyl, C.sub.1 -C.sub.6 alkyl, or --NR.sub.8 R.sub.9, wherein R.sub.8 and R.sub.9 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl; with the proviso that when R.sub.2 and at least one of R.sub.5 or R.sub.7 is C.sub.1 -C.sub.6 alkyl, and Ar is not substituted with trifluoromethyl or --NR.sub.8 R.sub.

Abstract: This invention relates to certain 2,6-di-alkyl-4-silyl-phenols which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.

Abstract: The present invention relates to certain bis[4-(2,6-dialkyl)phenol]silane derivatives which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.

Abstract: The present invention relates to certain bis[4-(2,6-dialkyl)phenol]silane derivatives which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.

Abstract: Aryloxyalkanol derivatives having the formulaAr--O(CH.sub.2).sub.n OHwherein n is an integer from 3 to 8 and Ar is (1) 1- or 2-naphthylenyl, (2) phenyl optionally substituted by from 1 to 3 C.sub.1-4 lower alkyl groups, or (3) a diphenyl moiety of structure ##STR1## wherein Y is a bond, CH.sub.2 or CH.sub.2 O, and esters thereof have antiretrovirus activity and are effective in a method for treatment of a retrovirus infection.

Abstract: This invention relates to certain 2,6-di-alkyl-4-silyl-phenols which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.

Abstract: Aryloxyalkanol derivatives having the formulaAr--O(CH.sub.2).sub.n OHwherein n is an integer from 3 to 8 and Ar is (1) 1- or 2-naphthylenyl, (2) phenyl optionally substituted by from 1 to 3 C.sub.1-4 lower alkyl groups, or (3) a diphenyl moiety of structure ##STR1## wherein Y is a bond, CH.sub.2 or CH.sub.2 O, and esters thereof have antiretrovirus activity and are effective in a method for treatment of a retrovirus infection.

Abstract: This invention relates to novel aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions.